Payment overview · 2025
General Payments
$727.68
42 reported records · 16 companies
Healthcare provider profile · identity verified
Abdullah Baig, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · MILLINGTON, TN · NPI 1538126784
Verified facts
What the public records show
CMS Open Payments records show Abdullah Baig, MD received $727.68 in general payments during 2025 across 42 reported records.
Novo Nordisk Inc accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 320 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $246.98 | 33.9% | 16 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.73 | 13.2% | 6 | 2025 |
| Fidia Pharma USA Inc. | Unresolved — no canonical attribution shown | $41.81 | 5.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.26 | 5.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.92 | 5.1% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $32.94 | 4.5% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $31.88 | 4.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.10 | 4.3% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $30.04 | 4.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $29.37 | 4.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.97 | 4.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.25 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.45 | 2.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.54 | 2.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $15.19 | 2.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.25 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $727.68 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $194.87 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $194.87 | 14 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $95.73 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $95.73 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.11 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.26 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.26 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.92 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $32.94 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $31.88 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.10 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $30.04 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.97 | 2 | 2025 |
Source payment records
|
|||||
| HYMOVIS Normalized: hymovis |
Device | Fidia Pharma USA Inc. | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| HYALGAN Normalized: hyalgan |
Device | Fidia Pharma USA Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 71 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 320 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 249 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 43 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
105 | 34 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
103 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
102 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
320 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
249 | 63 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 813 | 275 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 607 | 215 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 558 | 165 |
| Pantoprazole Sodium | Pantoprazole Sodium | 463 | 157 |
| Potassium Chloride | Potassium Chloride | 397 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 389 | 129 |
| Metoprolol Succinate | Metoprolol Succinate | 362 | 116 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 343 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 335 | 92 |
| Mounjaro | Tirzepatide | 320 | 67 |
| Ozempic | Semaglutide | 249 | 63 |
| Losartan Potassium | Losartan Potassium | 244 | 83 |
| Furosemide | Furosemide | 238 | 96 |
| Omeprazole | Omeprazole | 226 | 69 |
| Tizanidine Hcl | Tizanidine Hcl | 216 | 79 |
| Gabapentin | Gabapentin | 202 | 63 |
| Montelukast Sodium | Montelukast Sodium | 197 | 72 |
| Glimepiride | Glimepiride | 184 | 53 |
| Alprazolam | Alprazolam | 181 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 177 | 61 |
| Cefuroxime | Cefuroxime Axetil | 164 | 112 |
| Clonidine Hcl | Clonidine Hcl | 155 | 49 |
| Tramadol Hcl | Tramadol Hcl | 154 | 62 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 153 | 51 |
| Pregabalin | Pregabalin | 150 | 50 |
| Ezetimibe | Ezetimibe | 147 | 46 |
| Carvedilol | Carvedilol | 144 | 49 |
| Allopurinol | Allopurinol | 142 | 46 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 141 | 100 |
| Nebivolol Hcl | Nebivolol Hcl | 136 | 46 |
| Metformin Hcl | Metformin Hcl | 132 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 60 |
| Famotidine | Famotidine | 126 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 118 | 59 |
| Lisinopril | Lisinopril | 118 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 43 |
| Eliquis | Apixaban | 117 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 37 |
| Azithromycin | Azithromycin | 113 | 91 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 44 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 112 | 40 |
| Clonazepam | Clonazepam | 111 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 39 |
| Linzess | Linaclotide | 105 | 34 |
| Farxiga | Dapagliflozin Propanediol | 103 | 28 |
| Promethazine Hcl | Promethazine Hcl | 103 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 30 |
| Metformin Hcl Er | Metformin Hcl | 101 | 33 |
| Metolazone | Metolazone | 96 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 95 | 74 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 88 | 30 |
| Fluconazole | Fluconazole | 87 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 31 |
| Trazodone Hcl | Trazodone Hcl | 78 | 21 |
| Trulicity | Dulaglutide | 75 | 17 |
| Donepezil Hcl | Donepezil Hcl | 74 | 30 |
| Novolog Flexpen | Insulin Aspart | 73 | 15 |
| Prednisone | Prednisone | 73 | 45 |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 37 |
| Jardiance | Empagliflozin | 71 | 28 |
| Januvia | Sitagliptin Phosphate | 70 | 20 |
| Spironolactone | Spironolactone | 66 | 27 |
| Alendronate Sodium | Alendronate Sodium | 65 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 65 | 22 |
| Sertraline Hcl | Sertraline Hcl | 64 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 38 |
| Xarelto | Rivaroxaban | 63 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 22 |
| Simvastatin | Simvastatin | 61 | 22 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 61 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 22 |
| Chlorthalidone | Chlorthalidone | 54 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 53 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | 15 |
| Baclofen | Baclofen | 51 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 22 |
| Levetiracetam | Levetiracetam | 49 | 15 |
| Entresto | Sacubitril/Valsartan | 48 | suppressed |
| Methylprednisolone | Methylprednisolone | 48 | 40 |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 20 |
| Meloxicam | Meloxicam | 43 | 12 |
| Rybelsus | Semaglutide | 43 | 12 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 42 | 31 |
| Memantine Hcl | Memantine Hcl | 42 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 16 |
| Bupropion Xl | Bupropion Hcl | 40 | 12 |
| Dexamethasone | Dexamethasone | 39 | 34 |
| Ramipril | Ramipril | 39 | 19 |
| Levofloxacin | Levofloxacin | 38 | 28 |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | 17 |
| Mirtazapine | Mirtazapine | 38 | 22 |
| Fluvastatin Sodium | Fluvastatin Sodium | 37 | suppressed |
| Methotrexate | Methotrexate Sodium | 37 | 16 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Topiramate | Topiramate | 36 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 13 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 33 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Valacyclovir | Valacyclovir Hcl | 33 | 17 |
| Buspirone Hcl | Buspirone Hcl | 32 | 11 |
| Mupirocin | Mupirocin | 32 | 13 |
| Telmisartan | Telmisartan | 32 | 13 |
| Niacin Er | Niacin | 31 | suppressed |
| Repaglinide | Repaglinide | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 26 |
| Risedronate Sodium | Risedronate Sodium | 30 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 29 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 20 |
| Nystatin | Nystatin | 27 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | 23 |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | 14 |
| Nifedipine Er | Nifedipine | 25 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Acarbose | Acarbose | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Clonidine | Clonidine | 21 | 12 |
| Colchicine | Colchicine | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 18 |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 15 |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Qulipta | Atogepant | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | 13 |
| Nadolol | Nadolol | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Prevalite | Cholestyramine | 12 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $727.68 · 42 records | Novo Nordisk Inc | BREZTRI, FREESTYLE LIBRE 3, GEMTESA, HYALGAN, HYMOVIS, Hillrom - Vest System Model 105 Home Care, JARDIANCE, LEQVIO, MOUNJARO, OTEZLA, Ozempic, QUTENZA, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, VRAYLAR, Vest Therapy Und, Wegovy, YUPELRI, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error